Ctxr stock forecast is trending higher after the company

CTXR stock forecast is trending higher after the company disclosed progress in its clinical trials. Sector analysts estimate biotech deal flow in 2024 could lift valuation multiples, pushing the short-term target range to $1.15–$1.25. The company’s work is focused mainly on two conditions – growth hormone deficiency (GHD) in adults and children, and hypoparathyroidism (PTH), also in adults and children – and Ascendis has a GHD medication approved and on the market already. The GHD drug, Skytrofa, received its original approval in 2021, and is currently generating revenues in both the US and Europe. The company plans to submit a supplemental Biologics License Application to the FDA, for use of the drug to treat GHD in adults, during the current 3Q24. Hi there, Yurii Domaranskyi here. Risk vs Reward = 1 to 23.63 ✨ It means if you risk here 100$ you may make 2363$ Not bad, huh? Tracking moving average convergence trends, CTXR stock forecast looks constructive for traders with a mid-term view. Key is maintaining closes above both the 20- and 50-day averages to sustain upward bias.